Inspira™ Technologies to Present Advanced Respiratory Solutions to Key International Leaders at the Annual iECOs Conference in Tel Aviv, Israel

News provided by

Nov 08, 2022, 12:21 ET

Inspira Technologies CTO Daniella Yeheskely-Hayon, Ph.D., will deliver a guest lecture during Physiology & Technology session

RA'ANANA, Israel, Nov. 8, 2022 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that the company will present at the annual iECOs Conference in Tel Aviv, Israel on November 10th, 2022.

The company's CTO, Daniella Yeheskely-Hayon, Ph.D., a renowned specialist in blood oxygenation, will guest lecture at the Physiology and Technology session and present the company and its groundbreaking technology to key medical opinion leaders.

Inspira Technologies' scientific team will be available at the company's booth to demonstrate and answer questions about the technologies and products currently in development. To schedule a meeting with the company, please contact: [email protected]

About iECOs

iECOs, known as the Israeli ECMO Society, is a medical organization for medical professionals in the fields of ICU medicine including pediatrics, cardiac medicine and surgery, heart-lung specialists, emergency medicine and heart failure to share knowledge and professional experiences, to improve and promote extracorporeal oxygenation education and medical practice.

Inspira Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA™ ART), designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while minimizing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company's products have not yet been tested or used in humans and have not been approved by any regulatory entity.

For more information, please visit our corporate website: https://inspirao2.com

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2021, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website, www.sec.gov

For more details:

US Investor Relations
Miri Segal,
MS-IR LLC
+917-607-8654
[email protected]

US Public Relations
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
[email protected]

Logo - https://mma.prnewswire.com/media/1941810/Inspira_Technologies_Logo.jpg

SOURCE Inspira Technologies